The National Medical Products Administration of the PRC (NMPA) has approved JHL Biotech’s Phase I and Phase III Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat several forms of cancer, including advanced non-squamous non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, metastatic kidney cancer, advanced cervical cancer, and recurrent ovarian cancer. JHL’s China…